BAD NEWS - - AVITA HAS LOST PATENT CHALLENGE AGAINST RENOVACARE
- Not so sure why this press release is hidden from the mainstream wire services -
Avita Medical receives decision on Inter Partes Review (IPR) petition of RenovaCare patent
_______________________
Valencia, CA, USA, Perth, Australia and London, United Kingdom, 20 December 2017 — Avita Medical (ASX:AVH,OTCQX:AVMXY), a regenerative medicine company with a technology platform positioned to address opportunities and unmet medical needs in burns, chronic wounds, and aesthetics indications, received a decision denying institution of Inter Partes Review (IPR) in Case No. IPR2017-01243.
The Decision was issued by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office. Avita requested the IPR with the PTAB to invalidate all claims in U.S. Patent No. 9,610,430 (the ‘430 patent) owned by RenovaCare Sciences Corp.
“Avita continues to believe that all claims in the RenovaCare ‘430 patent are unpatentable,” said Avita CEO Dr. Mike Perry. “Avita will continue to assertively protect its intellectual property position and pursue all available options, including promptly filing a request for rehearing on the decision by the PTAB.”